TrialInternational journal of clinical oncology2023

Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma.

Noboru Nakaigawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.